Exploring Vancomycin Disposition in Neonates

Recruiting Phase 4 Interventional Study
Neonatal Infection
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
1 Day – 23 Months
Sex
Any
Trial phase
Phase 4
Study type
Interventional
Purpose
Basic Science
Participants needed
120 (estimated)
Sponsor
Universitaire Ziekenhuizen KU Leuven · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Vancomycin is already used for decades in neonates. However, there are remaining questions concerning vancomycin disposition in this population. The purpose of this study is first of all to perform a paired analysis of serum vancomycin concentrations using an immunoassay versus a reference liquid chromatography-tandem mass spectrometry method. Secondly, we aim to determine vancomycin protein bindi…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Neonates, admitted to the Neonatal Intensive Care Unit to whom vancomycin is administered for medical reasons, can be included in the study after informed consent of the parents. Exclusion Criteria: * No vancomycin therapy * No signed informed consent available
Contacts

Anne Smits, MD

003216341564

anne.smits@uzleuven.be

CONTACT

Karel Allegaert, MD, PhD

003216343210

karel.allegaert@uzleuven.be

CONTACT